Newronika Welcomes Keith Carlton as New Executive Chairman
Newronika, a leader in adaptive deep brain stimulation technology known as AlphaDBS™, is excited to announce the appointment of Mr. Keith Carlton as the company's new Executive Chairman. This significant move is expected to reinforce the company's strategic vision as it approaches new horizons in global expansion.
Bringing a wealth of executive leadership experience across the medical device and neuromodulation sectors, Mr. Carlton is well-prepared to guide Newronika through its next transformative chapter. His history of promoting innovation and fostering strategic growth aligns perfectly with Newronika's objectives moving forward.
A Visionary Leader for Newronika
Lorenzo Rossi, PhD, Co-Founder and CEO of Newronika, expressed enthusiasm regarding Mr. Carlton's leadership. "We are thrilled to welcome Keith as our Executive Chairman. His extensive experience and notable achievements in the medical technology arena will be essential as we work towards commercializing AlphaDBS and advancing clinical validation," he stated.
Strategic Impact on Patient Care
This groundbreaking platform aims to provide patients with Parkinson’s disease and other neurological disorders enhanced symptom relief while minimizing side effects. The appointment strengthens Newronika's mission of making a meaningful therapeutic impact on patients worldwide.
Carlo Sanfilippo, who serves as the Senior Investment Manager at Indaco Venture Partners and a member of the Newronika Board, extended a warm welcome to Mr. Carlton. He asserted confidence in Mr. Carlton's ability to navigate the forthcoming phase of growth. His track record is likely to be an asset as the company pursues ambitious goals.
Commitment to Innovation and Growth
Reflecting on his new role, Mr. Carlton stated, "It’s a privilege to join Newronika at such a transformative point in its journey. The company has the potential to redefine standards of care for neurological disorders through its pioneering adaptive DBS technology. I am eager to work alongside the Board and our talented team to foster innovation and expand patient access."
One of the initial focuses of Mr. Carlton’s leadership will be the successful launch of the Phase III U.S. Pivotal trial, which will be critical to demonstrating the efficacy of the AlphaDBS technology. This strategic trial aims to solidify the advantages of adaptive deep brain stimulation.
Recent Achievements Spotlighting Growth
Mr. Carlton's arrival comes at a pivotal time for Newronika, which recently achieved several milestones—such as receiving the CE Mark approval for AlphaDBS, obtaining U.S. FDA IDE clearance, and successfully concluding a €13.6 million Series B financing round. This series of accomplishments emphasizes Newronika's commitment to attempting to drive a paradigm shift in neuromodulation therapy on a global scale.
About Newronika SpA
Newronika is a pioneering organization that is transforming deep brain stimulation through advanced adaptive technology. Utilizing real-time neurophysiological feedback optimizes therapy, enhancing treatment outcomes for individuals suffering from neurological disorders. Headquartered in Milan, Newronika is dedicated to pushing the boundaries of adaptive DBS, focusing on regulatory approvals and clinical efforts across Europe, the U.S., and beyond. Stay tuned for further developments as Newronika continues to innovate within the realm of neuromodulation.
Frequently Asked Questions
What is Newronika?
Newronika is a company focused on developing innovative adaptive deep brain stimulation technology to improve outcomes for patients with neurological disorders.
Who is the new Executive Chairman of Newronika?
The new Executive Chairman of Newronika is Mr. Keith Carlton, who brings extensive experience in leadership roles within the medical technology sector.
What is AlphaDBS™?
AlphaDBS™ is Newronika's proprietary adaptive deep brain stimulation system designed to provide targeted therapy for patients with Parkinson's disease.
Why is Mr. Carlton's appointment important?
His appointment is critical as it strengthens Newronika's leadership and aligns with their goal of expanding their influence and operations in the neuromodulation market.
What are Newronika's recent accomplishments?
Recent achievements include receiving CE Mark approval for AlphaDBS, U.S. FDA IDE clearance, and completing a significant financing round to support its growth initiatives.
